Signal transducer and activator of transcription 3 (STAT3) gene polymorphisms are associated with treatment outcomes in acute myeloid leukemia

International Journal of Laboratory Hematology

Volumn 34, Issue 4, 2012, Pages 383-389

  Zhong, Y ^a   Feng, J ^a   Chen, B ^b   Cheng, L ^c   Li, Y ^d   Qian, J ^e   Ding, J ^b   Gao, F ^b   Xia, G ^b  

^a JIANGSU CANCER HOSPITAL   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c Southeast University   (China)

^d Huaian No1 People Branch Hospital   (China)

^e Zhenjiang No1 People Branch Hospital   (China)

Author keywords

Acute myeloid leukemia; Chemotherapy; Signal transducer and activator of transcription 3; Single nucleotide polymorphisms

Indexed keywords

CYTARABINE; DAUNORUBICIN; STAT3 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CHINESE; CYTOGENETICS; FEMALE; GENE FREQUENCY; GENOME ANALYSIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; STAT3 TRANSCRIPTION FACTOR; TREATMENT OUTCOME;

EID: 84862886755     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2012.01406.x     Document Type: Article

References (20)

1. Barragan E., Collado M., Cervera J., Martin G., Bolufer P., Roman J. & Sanz M.A. (2007) The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leukemia Research 31, 947-953.
2. Benekli M., Xia Z., Donohue K.A., Ford L.A., Pixley L.A., Baer M.R., Baumann H. & Wetzler M. (2002) Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99, 252-257.
3. Benekli M., Baer M.R., Baumann H. & Wetzler M. (2003) Signal transducer and activator of transcription proteins in leukemias. Blood 101, 2940-2954.
4. Bloomfield C.D. & Brunning R.D. (1985) The revised French-American-British classification of acute myeloid leukemia: is new better? Annals of Internal Medicine 103, 614-616.
5. Bromberg J. (2002) Stat proteins and oncogenesis. Journal of Clinical Investigation 109, 1139-1142.
6. Bromberg J..F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C. & Darnell J.J. (1999) Stat3 as an oncogene. Cell 98, 295-303.
7. Coppo P., Gouilleux-Gruart V., Huang Y., Bouhlal H., Bouamar H., Bouchet S., Perrot C., Vieillard V., Dartigues P., Gaulard P., Agbalika F., Douay L., Lassoued K. & Gorin N.C. (2009) STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia 23, 1667-1678.
8. Darnell J.J., Kerr I.M. & Stark G.R. (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421.
9. Davey F.R., Castella A., Lauenstein K., Hubbell C. & Oates R.P. (1983) Prognostic significance of the revised French-American-British classification for acute lymphocytic leukaemia. Clinical Laboratory Haematology 4, 343-351.
10. Haura E.B., Turkson J. & Jove R. (2005) Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nature Clinical Practice Oncology 2, 315-324.
11. Holtick U., Vockerodt M., Pinkert D., Schoof N., Stürzenhofecker B., Kussebi N., Lauber K., Wesselborg S., Löffler D., Horn F., Trümper L. & Kube D. (2005) STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 19, 936-944.
12. Jaffe E.S., Harris N.L., Stein H. & Vardiman J.W. (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC.
13. Kreil S., Waghorn K., Ernst T., Chase A., White H., Hehlmann R., Reiter A., Hochhaus A., Cross N.C. & German CML Study Group. (2010) A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α. Haematologica 95, 148-152.
14. Redell M.S., Ruiz M.J., Alonzo T.A., Gerbing R.B. & Tweardy D.J. (2011) Stat3 signaling in acute myeloid leukemia: ligand-dependent and independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117, 5701-5709.
15. Sommer V.H., Clemmensen O.J., Nielsen O., Wasik M., Lovato P., Brender C., Eriksen K.W., Woetmann A., Kaestel C.G., Nissen M.H., Ropke C., Skov S. & Ødum N. (2004) In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18, 1288-1295.
16. Spiekermann K., Biethahn S., Wilde S., Hiddemann W. & Alves F. (2001) Constitutive activation of STAT transcription factors in acute myelogenous leukemia. European Journal of Haematology 67, 63-71.
17. Steensma D.P., McClure R..F., Karp J.E., Tefferi A., Lasho T.L., Powell H.L., DeWald G.W. & Kaufmann S.H. (2006) JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 20, 971-978.
18. Sternberg D.W. & Gilliland D.G. (2004) The role of signal transducer and activator of transcription factors in leukemogenesis. Journal of Clinical Oncology 22, 361-371.
19. Yu H. & Jove R. (2004) The STATs of cancer-new molecular targets come of age. Nature Reviews Cancer 4, 97-105.
20. Zhong Y., Wu J., Chen B., Ma R., Cao H., Wang Z., Cheng L., Ding J. & Feng J. (2012) Investigation and analysis of single nucleotide polymorphisms in the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) genes with leukemia. Leukemia & Lymphoma [Epub ahead of print].